CC-401

Investigational

Details

Stereochemistry	ACHIRAL
Molecular Formula	C22H24N6O
Molecular Weight	388.4656
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

C(CN1CCCCC1)OC2=CC(=CC=C2)C3=NNC4=C3C=C(C=C4)C5=NNC=N5

InChI

InChIKey=XDJCLCLBSGGNKS-UHFFFAOYSA-N

InChI=1S/C22H24N6O/c1-2-9-28(10-3-1)11-12-29-18-6-4-5-16(13-18)21-19-14-17(22-23-15-24-27-22)7-8-20(19)25-26-21/h4-8,13-15H,1-3,9-12H2,(H,25,26)(H,23,24,27)

HIDE SMILES / InChI

Molecular Formula	C22H24N6O
Molecular Weight	388.4656
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: http://adisinsight.springer.com/drugs/800021625
Curator's Comment: Description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/17202416

CC-401 is a potent inhibitor of all three forms of c-Jun N-terminal Kinase (JNK) (Ki of 25 to 50 nM) and has at least 40-fold selectivity for JNK compared with other related kinases. Celgene was developing CC 401 for the treatment of cancer and inflammatory disorders. CC 401 was being developed in an IV formulation and was in a phase I trial in patients with refractory acute myelogenous leukaemia. However, trials have ended and the company is not pursuing CC 401, but will advance other JNK inhibitors.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
c-Jun N-terminal kinase 1 8 Target ID: CHEMBL2276 Sources: https://www.ncbi.nlm.nih.gov/pubmed/17202416	Inhibitor 8297
c-Jun N-terminal kinase 2 4 Target ID: CHEMBL4179 Sources: https://www.ncbi.nlm.nih.gov/pubmed/17202416	Inhibitor 8297
c-Jun N-terminal kinase 3 5 Target ID: CHEMBL2637 Sources: https://www.ncbi.nlm.nih.gov/pubmed/17202416	Inhibitor 8297

Conditions

Condition	Modality	Highest Phase	Product
Acute myelogenous leukemia 19 Sources: http://adisinsight.springer.com/drugs/800021625	Primary	Phase I 428	Unknown Approved Use Unknown
Renal fibrosis 7 Sources: https://www.ncbi.nlm.nih.gov/pubmed/17202416	Primary	Preclinical	Unknown Approved Use Unknown
Anti-glomerular basement membrane disease 1 Sources: https://www.ncbi.nlm.nih.gov/pubmed/17597698 https://www.ncbi.nlm.nih.gov/pubmed/19188913	Primary	Preclinical	Unknown Approved Use Unknown

Sourcing

Vendor/Aggregator	ID	URL
001 Chemical	DY107058	https://www.001chemical.com/chem/search?q=DY107058
1PlusChem LLC	1P001IX9	https://www.1pchem.com/search?query=1P001IX9
1PlusChem LLC	1P00BYYJ	https://www.1pchem.com/search?query=1P00BYYJ
AK Scientific	3059AH	https://aksci.com/item_detail.php?cat=3059AH
AK Scientific	SYN1028	https://aksci.com/item_detail.php?cat=SYN1028
AK Scientific	Y0278	https://aksci.com/item_detail.php?cat=Y0278
AbovChem LLC	HY-13022A	http://www.abovchem.com/pc/en/product_list.aspx?wd=HY-13022A
ApexBio Technology	B1260	https://www.apexbt.com/catalogsearch/result/?q=B1260
AstaTech	C72713	http://astatechinc.com/CPSResult.php?CRNO=C72713
AstaTech	I10351	http://astatechinc.com/CPSResult.php?CRNO=I10351
Axon MedChem	2025	https://www.axonmedchem.com/product/2025
BLD Pharm	BD316932	http://www.bldpharm.com/search/Search.html?keyword=BD316932
BLD Pharm	BD445426	http://www.bldpharm.com/search/Search.html?keyword=BD445426
BLD Pharm	BD627487	http://www.bldpharm.com/search/Search.html?keyword=BD627487
Capot Chemical	22434	https://www.capotchem.com/search.do?q=22434
Cayman Chemical	18867	http://www.caymanchem.com/app/template/Product.vm/catalog/18867
Chem Scene	CS-0261	http://www.chemscene.com/goproductList/searchProductList?productObj=CS-0261
ChemShuttle	112415	https://www.chemshuttle.com/catalogsearch/result/?q=112415
KeyOrganics	AS-16198	http://www.keyorganicsinc.com/bionet/catalogsearch/result?q=AS-16198
Lab Network	LN01342588	https://labnetwork.com/frontend-app/p/#!/moleculedetails/LN01342588
Matrix Scientific	132617	http://www.matrixscientific.com/132617.html
MedChem Express	HY-13022	https://www.medchemexpress.com/search.html?q=HY-13022&ft=&fa=&fp=
MolPort	MolPort-016-631-869	https://www.molport.com/shop/molecule-link/MolPort-016-631-869
MolPort	MolPort-021-804-942	https://www.molport.com/shop/molecule-link/MolPort-021-804-942
MolPort	MolPort-028-720-361	https://www.molport.com/shop/molecule-link/MolPort-028-720-361
MolPort	MolPort-044-561-531	https://www.molport.com/shop/molecule-link/MolPort-044-561-531
MolPort	MolPort-046-162-912	https://www.molport.com/shop/molecule-link/MolPort-046-162-912
Molcore	MC107058	http://www.molcore.com/CatMC107058.html
Molnova	M11859	https://www.molnova.com/en/serch-list.html?keywords=M11859
Molnova	M14359	https://www.molnova.com/en/serch-list.html?keywords=M14359
MuseChem	I004911	https://www.musechem.com/product/I004911.html
Ryan Scientific	101-94014	https://ryansci.com/products?q=101-94014&list_q=&search_type=exact
Selleck Chemicals	S6730	http://www.selleckchem.com/search.html?searchDTO.searchParam=S6730
ShangHai Biochempartner	BCP01960	http://www.biochempartner.com/search_BCP01960
ShangHai Biochempartner	BCP25004	http://www.biochempartner.com/search_BCP25004
Toronto Research Chemicals	C227860	https://www.trc-canada.com/product-detail/?CatNum=C227860
Toronto Research Chemicals	C988073	https://www.trc-canada.com/product-detail/?CatNum=C988073
eMolecules	300445387	https://orderbb.emolecules.com/search/#?query=300445387
eMolecules	36370236	https://orderbb.emolecules.com/search/#?query=36370236
eMolecules	43473231	https://orderbb.emolecules.com/search/#?query=43473231
eMolecules	44786270	https://orderbb.emolecules.com/search/#?query=44786270
eMolecules	68868544	https://orderbb.emolecules.com/search/#?query=68868544
eNovation Chemicals	D514551	https://www.enovationchem.com/Products.asp?SEARCHTEXT=D514551&searchbtn.x=0&searchbtn.y=0
eNovation Chemicals	D662939	https://www.enovationchem.com/Products.asp?SEARCHTEXT=D662939&searchbtn.x=0&searchbtn.y=0
mcule	MCULE-1957992955	https://mcule.com/MCULE-1957992955/
mcule	MCULE-6606502390	https://mcule.com/MCULE-6606502390/

PubMed

Title	Date	PubMed
Blockade of the c-Jun amino terminal kinase prevents crescent formation and halts established anti-GBM glomerulonephritis in the rat.	2009 Apr	19188913

Patents

Sample Use Guides

In Vivo Use Guide

An earlier phase I trial of CC 401, initiated in October 2002, was completed and the drug was found to be safe and well tolerated in healthy volunteers over the range of IV doses studied (dosage is unknown). CC-401 is prepared in a sodium citrate vehicle and administered to rats by twice-daily gavage at 100 mg/kg.

Route of Administration: Other

In Vitro Use Guide

1-2 μM CC-401 blocked apoptosis and necrosis in hepatocytes. Inhibition of JNK in colon cancer cell lines by CC-401 enhances cytotoxicity of the chemotherapy in vitro.

Substance Class	Chemical Created by `admin` on `Fri Dec 15 15:35:22 GMT 2023` Edited by `admin` on `Fri Dec 15 15:35:22 GMT 2023`
Record UNII	NOE38VQA1W
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

CC-401

Common Name

English

1-(5-(1H-1,2,4-TRIAZOL-5-YL)-1H-INDAZOL-3-YL)-3-(2-PIPERIDINOETHOXY)-BENZENE

Systematic Name

English

1H-INDAZOLE, 3-(3-(2-(1-PIPERIDINYL)ETHOXY)PHENYL)-5-(1H-1,2,4-TRIAZOL-3-YL)-

Systematic Name

English

1H-INDAZOLE, 3-(3-(2-(1-PIPERIDINYL)ETHOXY)PHENYL)-5-(1H-1,2,4-TRIAZOL-5-YL)-

Systematic Name

English

Classification Tree Code System Code

NCI_THESAURUS

C2149